Post marketing safety assessment of the novel postpartum depression drug, Zuranolone: evidence from real-world pharmacovigilance analysis based on the FDA adverse event reporting system

Post marketing safety assessment of the novel postpartum depression drug, Zuranolone: evidence from real-world pharmacovigilance analysis based on the FDA adverse event reporting system

ObjectiveZuranolone, the latest oral medication for postpartum depression, was approved in the United States in August 2023. Due to its pharmacokinetic characteristics and rapid onset of action, it is hailed as a breakthrough and enhanced version of the drug. However, there is limited information on...

Full description

Saved in:
Bibliographic Details
Main Authors: Duoqin Huang, Zixin Luo, Xi Gong, Kang Zou, Yu Peng, Shaoying Zeng
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-08-01
Series:Frontiers in Psychiatry
Subjects:
Zuranolone
FAERS database
safety analysis
postpartum depression
signal mining
adverse events
Online Access:https://www.frontiersin.org/articles/10.3389/fpsyt.2025.1517773/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fpsyt.2025.1517773/full

Similar Items